| Document Date: 2014-06-02 07:14:19
Open Document File Size: 144,28 KBShare Result on Facebook
City Vancouver / Melbourne / Edinburgh / / Company Western European / Bristol-Myers Squibb / / Country Switzerland / Canada / Australia / Scotland / / / / IndustryTerm hepatitis care / HCV care / healthcare budgets / healthcare professionals / hepatitis C care / HCV treatment / sterile injection equipment / pharmaceutical / hepatitis C treatment / / MedicalCondition high baseline chronic prevalence / HIV / disease / epidemic / hepatitis C. Acknowledgement / similar hepatitis C / chronic HCV / hidden hepatitis C / hepatitis C / hepatitis B / HCV / free hepatitis C / HIV epidemic / liver fibrosis / Bruggmann P. Accessing Hepatitis C / low hepatitis / hepatitis / infections / chronic hepatitis C / fibrosis / chronic baseline prevalence / / Organization American Association for the Study of Liver Diseases / World Trade Organization / Global Commission on Drug Policy / / Person Acknowledgement / Philip Bruggmann / / Position author / advisor /speaker / / Product ribavirin / / URL www.globalcommissionondrugs.org / /
SocialTag |
EDITORIALS Treatment as Prevention: The Breaking of Taboos Is Required in the Fight Against Hepatitis C Among People Who Inject Drugs See Article on Page 1598